http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2753391-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b97c948c84a801e5cad5634c3a536c77 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-04004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-04004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-78 |
| filingDate | 2015-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbc51cb435ca9e2408e0a914cba21327 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9b1e48dc7deb1e4c24f8fc867d95d9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8b8a0e4c6f4acd7e66380498e7f6622 |
| publicationDate | 2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2753391-T3 |
| titleOfInvention | Adenosine deaminase 2 (ADA2) compositions, variants thereof and methods of use thereof |
| abstract | A variant adenosine deaminase 2 (ADA2) protein or a catalytically active portion thereof, comprising one or more modifications to the amino acid sequence of an unmodified ADA2 polypeptide or a catalytically active portion thereof, wherein: the protein Unmodified ADA2 is selected from an ADA protein comprising: the amino acid sequence set forth in SEQ ID NO: 5; an amino acid sequence showing at least 95% sequence identity with the amino acid sequence set forth in SEQ ID NO: 5, or is a catalytically active portion of the amino acid sequence showing at least 95% sequence identity with the amino acid sequence set forth in SEQ ID NO: 5; or comprises the amino acid sequence set forth in any of SEQ ID NO: 5, 326-334, 340, 375 and 380-383 or is a catalytically active portion thereof; the modified ADA2 protein has up to 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid modifications compared to the unmodified ADA2 protein; Amino acid modifications are selected from one or more amino acid replacements, deletions, and insertions; the variant ADA2 protein comprises an amino acid replacement at one or both positions corresponding to amino acid residue 219 and 262 with reference to the amino acid positions set forth in SEQ ID NO: 5; variant ADA2 protein, when in dimer form, exhibits increased adenosine deaminase activity or increased adenosine deaminase activity and reduced heparin binding compared to the dimer form of the unmodified ADA2 protein of SEQ ID NO: 5 or the dimer form of the catalytically active portion thereof; and the variant ADA2 protein, when in dimer form, shows adenosine deaminase activity to convert adenosine to inosine. |
| priorityDate | 2014-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1188.